(or N',N')alkylaminoalkyl ureas, thioureas and cyanoguanidines represented by the following formula: ##STR1## wherein Ar is aryl selected from the group consisting of 1- and 2-naphthyl, 2,3-dihydro-1H-inden-4(or
5-Chloro-4-Fluoro-2-Nitroaniline 5-クロロ-4-フルオロ-2-ニトロアニリン 104222-34-6 C6H4ClFN2O2 6,8-Dibromo-[1,2,4]triazolo[1,5-a]Pyridine 6,8-ジブロモ-[1,2,4]トリアゾロ[1,5-A]ピリジン 1310680-10-4 C6H3Br2N3 1-Methyl-1H-Pyrrolo[2,3-b]Pyridine 1-メチル-1H-ピ...
Preparation Products 6-CYANONICOTINIC ACID-->N,N-DIETHYL-4-NITROANILINE-->5-Nitrobenzimidazole-->N,N-DIETHYL-2-PHENYLACETAMIDE-->2,4(1H,3H)-Quinazolinedione, 6-methyl--->5-Methylbenzimidazole-->2-Methylbenzimidazole-->EthanaMine, N-[(5-broMo-3-Methoxy-2H-pyrrol-2-ylidene)Methyl]-N-ethyl-...
intra-arterial Budr, intravenous iododeoxyuridine (IudR), nitroimidazole, 5-substituted-4-nitroimidazoles, 2H-isoindolediones, [[(2-bromoethyl)-amino]methyl]-nitro-1H-imidazole-1-ethanol, nitroaniline derivatives, DNA-affinic hypoxia selective cytotoxins, halogenated DNA ligand, 1,2,4 benzotriazine ox...
Answer to: Draw the structure of the next oligopeptide in line. Identify the C and N terminals and also identify a peptide bond and a disulfide...
4. The compound of claim 3 wherein: A is —N=; Z1 is —O—; Z2 is —O—; R1 is hydrogen or —OR9; R2 is —C(NH)NH2; R3 is (1,2)-tetrahydropyrimidinyl (optionally substituted by methyl), (1,2)-imidazolyl (optionally substituted by methyl) or (1,2)-imidazolinyl (optiona...